Heart attack survivors face a fundamental challenge: once cardiac muscle dies, the body struggles to regenerate it, often leading to progressive heart failure. This biological limitation has driven researchers to explore whether tiny regulatory molecules called microRNAs could unlock the heart's dormant regenerative potential. MicroRNAs represent a sophisticated cellular control system, capable of fine-tuning multiple biological processes simultaneously. In cardiac repair, these molecules orchestrate the delicate balance between inflammation, cell death, blood vessel formation, and scar tissue development that determines whether heart tissue heals or deteriorates after an attack. Recent therapeutic approaches focus on either blocking harmful microRNAs that promote excessive scarring and cell death, or delivering beneficial ones that encourage new blood vessel growth and protect surviving heart cells. Some strategies involve direct injection of synthetic microRNAs into damaged heart tissue, while others use modified stem cells engineered to produce therapeutic microRNAs locally. The most promising applications target the early inflammatory phase after heart attack, when intervention could redirect the healing response toward regeneration rather than scarring. However, significant challenges remain in translating these molecular insights into clinical reality. MicroRNA therapies face delivery obstacles, potential off-target effects in other organs, and the complexity of timing interventions correctly. While laboratory studies show encouraging results in promoting new cardiomyocyte formation and improving heart function, human trials remain limited. The field represents an incremental but meaningful advance in cardiac medicine, potentially offering the first genuine regenerative therapy for heart attack damage rather than merely managing its consequences.